OTCMKTS:ENOB - Enochian Biosciences Stock Price, News, & Analysis

+0.15 (+2.84 %)
(As of 06/17/2019 04:00 PM ET)
Today's Range
Now: $5.43
50-Day Range
MA: $6.09
52-Week Range
Now: $5.43
Volume46,366 shs
Average Volume56,669 shs
Market Capitalization$210.62 million
P/E RatioN/A
Dividend YieldN/A
Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:ENOB



Sales & Book Value

Annual SalesN/A



Market Cap$210.62 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ENOB News and Ratings via Email

Sign-up to receive the latest news and ratings for ENOB and its competitors with MarketBeat's FREE daily newsletter.

Enochian Biosciences (OTCMKTS:ENOB) Frequently Asked Questions

What is Enochian Biosciences' stock symbol?

Enochian Biosciences trades on the OTCMKTS under the ticker symbol "ENOB."

Has Enochian Biosciences been receiving favorable news coverage?

News coverage about ENOB stock has trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Enochian Biosciences earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Enochian Biosciences.

Who are some of Enochian Biosciences' key competitors?

What other stocks do shareholders of Enochian Biosciences own?

Who are Enochian Biosciences' major shareholders?

Enochian Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Mycio Wealth Partners LLC (0.05%) and Marshall Wace LLP (0.02%). Company insiders that own Enochian Biosciences stock include Henrik Gronfeldt-Sorensen and Rene Sindlev. View Institutional Ownership Trends for Enochian Biosciences.

Which major investors are buying Enochian Biosciences stock?

ENOB stock was acquired by a variety of institutional investors in the last quarter, including Mycio Wealth Partners LLC and Marshall Wace LLP. Company insiders that have bought Enochian Biosciences stock in the last two years include Henrik Gronfeldt-Sorensen and Rene Sindlev. View Insider Buying and Selling for Enochian Biosciences.

How do I buy shares of Enochian Biosciences?

Shares of ENOB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enochian Biosciences' stock price today?

One share of ENOB stock can currently be purchased for approximately $5.43.

How big of a company is Enochian Biosciences?

Enochian Biosciences has a market capitalization of $210.62 million. View Additional Information About Enochian Biosciences.

What is Enochian Biosciences' official website?

The official website for Enochian Biosciences is http://www.enochianbio.com/.

How can I contact Enochian Biosciences?

The company can be reached via phone at 510-203-4857.

MarketBeat Community Rating for Enochian Biosciences (OTCMKTS ENOB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  5 (Vote Underperform)
Total Votes:  11
MarketBeat's community ratings are surveys of what our community members think about Enochian Biosciences and other stocks. Vote "Outperform" if you believe ENOB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENOB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel